The Biosimilars Council: Why Trade Organizations Are Key for Biosimilars

via Biosimilar Development
May 16, 2016
By Anna Rose Welch

As the biosimilar market in the U.S. develops, a growing number of biopharma companies are stepping forward to shape the policies that will impact the market’s growth. Many of these companies, whether they be big pharma, generics and biotech companies, and/or pure-play biosimilar companies, are becoming members of a number of trade organizations that have been cropping up over the past year. We sat down with Dr. Bert Liang, chairman of the council and CEO of biosimilar company Pfenex, to discuss the Generic Pharmaceutical Association Biosimilar Council as one of these groups, and a support system for the burgeoning market in the U.S.

Read full article >